Pinnacle Medicines | $89,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
Mirage | $75,000,000 | (Mar 27, 2026)
BenchSci
Canada
- Toronto, Ontario
- 24/01/2022
- Series C
- $63,000,000
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. To achieve this, we're exponentially increasing the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence.
Backed by F-Prime, Gradient Ventures (Google’s AI fund), Inovia Capital, and TCV, our platform accelerates science at 16 of the top-20 pharmaceutical companies, and over 4,300 leading research centers worldwide.
We’re a remote-first company recognized for our impact and culture as a Deloitte Tech Fast 50TM, CIX Top 10 Growth, Great Place to Work®, and top-ranked organization on Glassdoor.
- Industry Software Development
- Website https://www.benchsci.com/
- LinkedIn https://www.linkedin.com/company/benchsci/about/
Related People
Tom Leung, MSc PhDFounder
Canada -
Toronto, Ontario
--BenchSci: Search By Evidence--
Researchers often look for evidence-of-use in literature before buying a new antibody or reagent. BenchSci aim to provide value for scientists, providing quick and easy access to evidence-of-use for different antibodies and reagents in peer-reviewed literature. Through BenchSci, scientists will be able to search antibodies or reagents by evidence and validations.
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)
Payy | $6,000,000 | (Mar 27, 2026)
Conntour | $7,000,000 | (Mar 27, 2026)
KilgourMD | Undisclosed Amount | (Mar 27, 2026)
Terrestrial | $50,000,000 | (Mar 27, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)